Patents by Inventor Ken Rice

Ken Rice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • [1H-pyrazolo[3, 4-D]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (P70s6k, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases
    Patent number: 7994172
    Abstract: The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    Type: Grant
    Filed: December 27, 2005
    Date of Patent: August 9, 2011
    Assignee: Exelixis, Inc.
    Inventors: Ken Rice, Erick Wang Co, Moon Hwan Kim, Lynn Canne Bannen, Joerg Bussenius, Donna Tra Le, Amy Lew Tsuhako, John Nuss, Yong Wang, Wei Xu, Rhett Ronald Klein
  • [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases
    Publication number: 20080188482
    Abstract: The invention provides compounds of formula (I) and methods for inhibition of kinases, more specifically p70S6 kinases, and more preferably p70S6, Akt-1 and Akt-2 kinases. The invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration, chemoinvasion and metabolism. Compounds of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions.
    Type: Application
    Filed: December 27, 2005
    Publication date: August 7, 2008
    Applicant: EXELIXIS, INC.
    Inventors: Ken Rice, Erick Wang Co, Moon Hwan Kim, Lynne Canne Bannen, Joerg Bussenirs, Donna Tra Le, Amy Lew Tsuhako, John Nuss, Yong Wang, Wei Xu, Rhett Ronald Klein
  • Method of evaluating contact center performance
    Publication number: 20070124161
    Abstract: A method and apparatus are provided for objectively grading a performance of a contact center based upon input from a plurality of customers of the contact center. The method includes the steps of receiving a consumer importance rating and a consumer satisfaction rating on the performance of the contact center from a multiplicity of customers of the plurality of customers of the contact center for each entry within a set of categories including empathy and advocacy, efficiency and automation, determining a maximum point score for each entry of the set of categories based upon a relative value of the importance ratings provided by the plurality of customers and assigning a point score to each entry of the set of categories based upon the maximum point score for the entry and the satisfaction ratings of the plurality of customers for the category.
    Type: Application
    Filed: October 17, 2006
    Publication date: May 31, 2007
    Applicant: Rockwell Electronic Commerce Technologies, Inc.
    Inventors: Margaret Mueller, Marna Harmey, Ken Rice, Owen Shapiro, Michael Sheridan, Laurie Cairns
  • Compositions and methods for treating mast-cell mediated conditions
    Patent number: 5656660
    Abstract: The present invention describes compounds, methods and compositions effective to treat mast cell mediated inflammatory conditions, such as conjunctivitis, asthma and allergic rhinitis. The compounds of the invention comprise novel mono- and di-aminomethylbenzyl, aminobenzyl, guanidylbenzyl and benzyl tryptase inhibitors. The compositions for treating mast cell mediated inflammatory conditions include oral, inhalant and topical preparations as well as devices comprising such preparations.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: August 12, 1997
    Assignee: Arris Pharmaceutical Corporation
    Inventors: Robert T. Lum, Heinz W. Gschwend, Barr E. Bauer, Elaine Kuo, Ken Rice